Southeast TechInventures, a company focused on helping commercialize scientific breakthroughs at universities, has landed an investment from the Piedmont Angel Network.

The amount of the deal was not disclosed.

The investment came through the Piedmont Angel Network (PAN) Two fund. PAN is based in Greensboro.

Southeast TechInventures acts as a technology accelerator and is working with inventors in biotechnology, display technologies, information technology and nanotechnology.

“We are pleased to have the Piedmont Angel Network as an investor,” said Karen LeVert, the founder and president of Southeast TechInventures. “Along with providing funding to assist in STI’s growth PAN also provides STI access to a number of well respected business and community leaders with multifaceted experience in all industries we are focused on.”

STI has worked with several startups in the region, including Bioptigen, Advanced Liquid Logic, ImagineOptix and MBright.

LeVert received the Outstanding Service to Entrepreneurs award from the Council for Entrepreneurial Development last year.

The investment is the third for the new fund, and PAN said it would announce a fourth investment in the near future.

“Karen LeVert and her team’s ability to mentor entrepreneurs to commercialize innovations at the university level is unmatched,” said Dixon Johnston, a member of PAN and a co-founder of the North Carolina Nannotech Accelerator. “STI has developed a model for prototype development using SBIR (Small Business Innovation Research) funding and has achieved higher than average success rates.

“In addition, STI has pre-negotiated mutually beneficial agreements with
the universities for royalties and licensing fees on the intellectual property, allowing entrepreneurs to focus on turning their work into finished products and services,” he added. “STI has shown the “accelerator” model to be successful in bringing new technologies to commercialization.”

PAN has made investments totaling more than $5 million since it was launched in 2002.

PAN recently invested in Bioptigen, which is based in Durham, and Effectur, a Greensboro company.